Biguanides and NIDDM
- PMID: 1600835
- DOI: 10.2337/diacare.15.6.755
Biguanides and NIDDM
Abstract
The main biguanides, metformin and phenformin, were introduced in 1957 as oral glucose-lowering agents to treat non-insulin-dependent diabetes mellitus (NIDDM). Phenformin was withdrawn in many countries because of an association with lactic acidosis, but metformin does not have the same risk if appropriately prescribed. Metformin is now widely used as a monotherapy and in combination with a sulfonylurea. Unlike sulfonylureas, metformin is not bound to plasma proteins, is not metabolized, and is eliminated rapidly by the kidney. The glucose-lowering effect occurs without stimulation of insulin secretion and results mainly from increased glucose utilization. The presence of insulin is required, and enhancement of insulin action at the postreceptor level occurs in peripheral tissues such as muscle. In peripheral tissues metformin increases insulin-mediated glucose uptake and oxidative metabolism. Metformin also increases glucose utilization by the intestine, primarily via nonoxidative metabolism. The extra lactate produced is largely extracted by the liver and serves as a substrate to sustain gluconeogenesis. This limits the extent to which metformin reduces hepatic glucose production but provides a safeguard against excessive glucose lowering. Because metformin does not cause clinical hypoglycemia, it is actually an antihyperglycemic drug. It does not cause weight gain, it helps combat hypertriglyceridemia, and it has been ascribed some vasoprotective properties. Metformin offers a useful treatment for insulin-resistant overweight NIDDM patients.
Similar articles
-
Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.J Fam Pract. 1996 Jun;42(6):612-8. J Fam Pract. 1996. PMID: 8656173 Review.
-
[Value of biguanide in therapy of diabetes mellitus].Med Klin (Munich). 1997 Aug 15;92(8):472-9, 505. doi: 10.1007/BF03044916. Med Klin (Munich). 1997. PMID: 9340472 Review. German.
-
[Therapeutic utility of biguanides in the treatment of NIDDM].Nihon Rinsho. 1999 Mar;57(3):657-62. Nihon Rinsho. 1999. PMID: 10199150 Review. Japanese.
-
Oral hypoglycemic agents in type II diabetes mellitus.Am Fam Physician. 1995 Nov 15;52(7):2075-8. Am Fam Physician. 1995. PMID: 7484707
-
Oral antidiabetic agents: current role in type 2 diabetes mellitus.Drugs. 2005;65(3):385-411. doi: 10.2165/00003495-200565030-00005. Drugs. 2005. PMID: 15669880 Review.
Cited by
-
Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2).Pharm Res. 2002 Aug;19(8):1244-7. doi: 10.1023/a:1019870831174. Pharm Res. 2002. PMID: 12240953 No abstract available.
-
Clinical pharmacokinetics of metformin.Clin Pharmacokinet. 1996 May;30(5):359-71. doi: 10.2165/00003088-199630050-00003. Clin Pharmacokinet. 1996. PMID: 8743335 Review.
-
Body composition in adults with newly diagnosed type 2 diabetes: effects of metformin.J Diabetes Metab Disord. 2014 Aug 21;13(1):88. doi: 10.1186/s40200-014-0088-z. eCollection 2014. J Diabetes Metab Disord. 2014. PMID: 25247153 Free PMC article.
-
Evaluation of the Association Metformin: Plantago ovata Husk in Diabetic Rabbits.J Diabetes Res. 2015;2015:167526. doi: 10.1155/2015/167526. Epub 2015 Oct 20. J Diabetes Res. 2015. PMID: 26576433 Free PMC article.
-
Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial.Diabetes Care. 2021 Jul;44(7):1462-1471. doi: 10.2337/dc20-2257. Epub 2021 May 18. Diabetes Care. 2021. PMID: 34006565 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical